STAAR Surgical Posts Strong Q2 2026 Sales Amid Geopolitical Challenges
Event summary
- STAAR Surgical expects Q2 2026 net sales of over $90 million, up from $44.3 million in Q2 2025.
- China and the Americas drove growth, while EMEA saw low single-digit declines due to Middle East turmoil.
- ERP system implementation caused operational challenges but did not derail strong performance.
- Distributor inventory in China is now within targeted range after excess stock issues in Q2 2025.
The big picture
STAAR Surgical's strong Q2 2026 sales reflect its global commercial operations' resilience amid geopolitical challenges. The company's focus on revenue growth, profit expansion, and innovation acceleration aligns with broader industry trends toward minimally invasive vision correction solutions. However, macroeconomic pressures remain a wildcard in sustaining this momentum.
What we're watching
- Geopolitical Risk
- Whether Middle East turmoil and macroeconomic headwinds will persist, affecting EMEA and Asia-Pacific sales.
- Operational Execution
- The pace at which STAAR resolves remaining ERP system issues in Q3 2026.
- Market Momentum
- How China and Americas growth will offset potential declines in other regions.
Related topics